LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

Strona główna・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

SectorHealthcare

8.28 -0.96

Buy Sell

Overview

Share price change

24h

Current

Min

8.2

Max

8.57

Key metrics
By Trading Economics
Income	11M -20M
Sales	5.9M 40M
EPS	-0.19
Profit margin	-49.569
Employees	184
EBITDA	16M -19M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+170.5% upside

Market Stats
By TradingEconomics
Market Cap	153M 901M
Previous open	9.24
Previous close	8.28

News Sentiment

By Acuity

50%

167 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 gru 2025, 23:21 UTC

Earnings

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 gru 2025, 23:14 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 gru 2025, 22:01 UTC

Major Market Movers

Costco Wholesale Reports Higher Monthly Sales

3 gru 2025, 21:38 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 gru 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 gru 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 gru 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 gru 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 gru 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 gru 2025, 23:10 UTC

Earnings

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 gru 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 gru 2025, 23:06 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 gru 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

3 gru 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 gru 2025, 22:20 UTC

Earnings

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 gru 2025, 22:19 UTC

Earnings

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 gru 2025, 22:17 UTC

Earnings

Salesforce Working to Add Voice to Agentforce, CEO Says

3 gru 2025, 22:16 UTC

Earnings

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 gru 2025, 22:15 UTC

Earnings

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 gru 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 gru 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 gru 2025, 21:49 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 gru 2025, 21:23 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 gru 2025, 21:19 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 gru 2025, 21:06 UTC

Earnings

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 gru 2025, 21:04 UTC

Earnings

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 gru 2025, 21:04 UTC

Earnings

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 gru 2025, 21:03 UTC

Earnings

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

170.5% upside

12 Months Forecast

Average 23.75 USD 170.5%

High 34 USD

Low 16 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

167 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.